Claims for Patent: 10,442,858

Summary for Patent: 10,442,858

Title:	Anti-CD47 antibodies and methods of use
Abstract:	Disclosed herein are anti-CD47 antibody molecules, their manufacture and use in treating disorders associated with CD47 expression, for example, certain hematological cancers and solid tumors.
Inventor(s):	Grosveld; Frank (Rotterdam, NL), Chappel; Scott (Milton, MA), Hill; Jonathan (Salem, MA), Holland; Pamela M. (Belmont, MA), Lake; Andrew (Westwood, MA), Paterson; Alison (Dedham, MA)
Assignee:	Erasmus University Medical Center (Rotterdam, NL) Surface Oncology, Inc. (Cambridge, MA)
Application Number:	15/711,971
Patent Claims:	1. A method of treating cancer in a subject in need thereof, wherein the cancer comprises cells that express CD47, the method comprising administering to the subject an effective amount of an isolated monoclonal antibody that specifically binds human CD47, wherein the monoclonal antibody comprises a heavy chain variable region (VH) comprising the amino acid sequence set forth in SEQ ID NO: 4, and a light chain variable region (VL) comprising the amino acid sequence set forth in SEQ ID NO: 6, wherein the antibody comprises a wild-type human IgG4heavy chain constant region. 2. The method of claim 1, wherein the isolated monoclonal antibody inhibits the interaction between human CD47 and SIRP.alpha.. 3. The method of claim 1, wherein the isolated monoclonal antibody does not cause significant, or detectable, hemagglutination of human erythrocytes relative to a reference monoclonal antibody that specifically binds human CD47 and causes significant, or detectable, hemagglutination of human erythrocytes, or antigen binding fragment thereof. 4. The method of claim 1, wherein the isolated monoclonal antibody is a human antibody. 5. The method of claim 1, wherein the isolated monoclonal antibody comprises a human kappa constant region. 6. The method of claim 5, wherein the human kappa constant region comprises the amino acid sequence set forth in SEQ ID NO: 22. 7. The method of claim 1, wherein the wild-type human IgG4 heavy chain constant region comprises the amino acid sequence set forth in SEQ ID NO: 20. 8. The method of claim 1, wherein the isolated monoclonal antibody is administered in combination with a chemotherapeutic agent or therapeutic antibody molecule. 9. The method of claim 1, wherein the isolated monoclonal antibody is administered in combination with an opsonizing antibody molecule. 10. The method of claim 9, wherein the opsonizing antibody molecule is an anti-CD19 antibody molecule, an anti-CD20 antibody molecule, an anti-CD38 antibody molecule, an anti-Her2/neu antibody molecule, an anti-EGFR antibody molecule, an anti-CD30antibody molecule, or an anti-CD33 antibody molecule. 11. The method of claim 10, wherein the opsonizing antibody molecule is an anti-CD20 antibody molecule. 12. The method of claim 11, wherein the antibody molecule is rituximab. 13. The method of claim 10, wherein the antibody molecule is an anti-CD38 antibody molecule. 14. The method of claim 13, wherein the anti-CD38 antibody molecule is daratumumab. 15. The method of claim 10, wherein the antibody molecule is an anti-CD19 antibody molecule. 16. The method of claim 10, wherein the antibody molecule is an anti-Her2/neu antibody molecule. 17. The method of claim 10, wherein the antibody molecule is an anti-EGFR antibody molecule. 18. The method of claim 10, wherein the antibody molecule is an anti-CD30 antibody molecule. 19. The method of claim 10, wherein the antibody molecule is an anti-CD33 antibody molecule. 20. The method of claim 1, wherein the cancer is a hematological cancer. 21. The method of claim 20, wherein the hematological cancer is selected from the group consisting of: acute lymphoblastic leukemia (ALL), T-ALL, B-ALL, acute myelogenous leukemia (AML), Non-Hodgkin lymphoma, B-lymphoblastic leukemia/lymphoma; diffuse large B cell lymphoma (DLBCL); B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), Burkitt's lymphoma, follicular lymphoma, SLL, marginal zone lymphoma, CNS lymphoma, Richter's Syndrome, multiple myeloma, myelofibrosis, polycythemia vera, cutaneous T-cell lymphoma, MGUS, myelodysplastic syndrome (MDS), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and anaplastic large cell lymphoma. 22. The method of claim 21, wherein the hematological cancer is acute myelogenous leukemia (AML), diffuse large B cell lymphoma (DLBCL) or Burkitt's lymphoma. 23. The method of claim 1, wherein the cancer is a solid tumor. 24. The method of claim 23, wherein the cancer is a cancer of a tissue selected from the group consisting of: lung, pancreas, breast, liver, ovary, testicle, kidney, bladder, spine, brain, cervix, endometrium, colon/rectum, anus, esophagus, gallbladder, gastrointestinal tract, skin, prostate, pituitary, stomach, uterus, vagina, and thyroid. 25. The method of claim 1, wherein the cancer is selected from the group consisting of: pancreatic cancer, ovarian cancer, breast cancer, stomach cancer, colon cancer, prostate cancer, and uterine cancer. 26. The method of claim 1, wherein the isolated monoclonal antibody is administered in combination with a pharmaceutically acceptable carrier or diluent. 27. The method of claim 1, wherein the isolated monoclonal antibody is administered subcutaneously. 28. The method of claim 1, wherein the isolated monoclonal antibody is administered intravenously. 29. A method of treating cancer in a subject in need thereof, wherein the cancer comprises cells that express CD47, the method comprising administering to the subject an effective amount of an isolated monoclonal antibody that specifically binds human CD47, wherein the monoclonal antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 24; and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 26. 30. The method of claim 29, wherein the isolated monoclonal antibody inhibits the interaction between human CD47 and SIRP.alpha.. 31. The method of claim 29, wherein the isolated monoclonal antibody does not cause significant, or detectable, hemagglutination of human erythrocytes relative to a reference monoclonal antibody that specifically binds human CD47 and causes significant, or detectable, hemagglutination of human erythrocytes, or antigen binding fragment thereof. 32. The method of claim 29, wherein the isolated monoclonal antibody is a human antibody. 33. The method of claim 29, wherein the isolated monoclonal antibody is administered in combination with a chemotherapeutic agent or therapeutic antibody molecule. 34. The method of claim 29, wherein the isolated monoclonal antibody is administered in combination with an opsonizing antibody molecule. 35. The method of claim 34, wherein the opsonizing antibody molecule is an anti-CD19 antibody molecule, an anti-CD20 antibody molecule, an anti-CD38 antibody molecule, an anti-Her2/neu antibody molecule, an anti-EGFR antibody molecule, an anti-CD30 antibody molecule, or an anti-CD33 antibody molecule. 36. The method of claim 35, wherein the opsonizing antibody molecule is an anti-CD20 antibody molecule. 37. The method of claim 36, wherein the antibody molecule is rituximab. 38. The method of claim 35, wherein the antibody molecule is an anti-CD38 antibody molecule. 39. The method of claim 35, wherein the anti-CD38 antibody molecule is daratumumab. 40. The method of claim 35, wherein the antibody molecule is an anti-CD19 antibody molecule. 41. The method of claim 35, wherein the antibody molecule is an anti-Her2 /neu antibody molecule. 42. The method of claim 35, wherein the antibody molecule is an anti-EGFR antibody molecule. 43. The method of claim 35, wherein the antibody molecule is an anti-CD30 antibody molecule. 44. The method of claim 35, wherein the antibody molecule is an anti-CD33 antibody molecule. 45. The method of claim 29, wherein the cancer is a hematological cancer. 46. The method of claim 45, wherein the hematological cancer is selected from the group consisting of: acute lymphoblastic leukemia (ALL), T-ALL, B-ALL, acute myelogenous leukemia (AML), Non-Hodgkin lymphoma, B-lymphoblastic leukemia/lymphoma; diffuse large B cell lymphoma (DLBCL); B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), Burkitt's lymphoma, follicular lymphoma, SLL, marginal zone lymphoma, CNS lymphoma, Richter's Syndrome, multiple myeloma, myelofibrosis, polycythemia vera, cutaneous T-cell lymphoma, MGUS, myelodysplastic syndrome (MDS), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and anaplastic large cell lymphoma. 47. The method of claim 46, wherein the hematological cancer is acute myelogenous leukemia (AML), diffuse large B cell lymphoma (DLBCL) or Burkitt's lymphoma. 48. The method of claim 29, wherein the cancer is a solid tumor. 49. The method of claim 48, wherein the cancer is a cancer of a tissue selected from the group consisting of: lung, pancreas, breast, liver, ovary, testicle, kidney, bladder, spine, brain, cervix, endometrium, colon/rectum, anus, esophagus, gallbladder, gastrointestinal tract, skin, prostate, pituitary, stomach, uterus, vagina, and thyroid. 50. The method of claim 29, wherein the cancer is selected from the group consisting of: pancreatic cancer, ovarian cancer, breast cancer, stomach cancer, colon cancer, prostate cancer, and uterine cancer. 51. The method of claim 29, wherein the isolated monoclonal antibody is administered subcutaneously. 52. The method of claim 29, wherein the isolated monoclonal antibody is administered intravenously. 53. A method of treating cancer in a subject in need thereof, wherein the cancer comprises cells that express CD47, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising an isolated monoclonal antibody that specifically binds human CD47; and a pharmaceutically acceptable carrier or diluent, wherein the monoclonal antibody comprises a heavy chain comprising the amino acid sequence set forth in SEQ ID NO: 24, and a light chain comprising the amino acid sequence set forth in SEQ ID NO: 26. 54. The method of claim 53, wherein the isolated monoclonal antibody inhibits the interaction between human CD47 and SIRP.alpha.. 55. The method of claim 53, wherein the isolated monoclonal antibody does not cause significant, or detectable, hemagglutination of human erythrocytes relative to a reference monoclonal antibody that specifically binds human CD47 and causes significant, or detectable, hemagglutination of human erythrocytes, or antigen binding fragment thereof. 56. The method of claim 53, wherein the isolated monoclonal antibody is a human antibody. 57. The method of claim 53, wherein the pharmaceutical composition is administered in combination with a chemotherapeutic agent or therapeutic antibody molecule. 58. The method of claim 53, wherein the pharmaceutical composition is administered in combination with an opsonizing antibody molecule. 59. The method of claim 53, wherein the opsonizing antibody molecule is an anti-CD19 antibody molecule, an anti-CD20 antibody molecule, an anti-CD38 antibody molecule, an anti-Her2/neu antibody molecule, an anti-EGFR antibody molecule, an anti-CD30 antibody molecule, or an anti-CD33 antibody molecule. 60. The method of claim 59, wherein the opsonizing antibody molecule is an anti-CD20 antibody molecule. 61. The method of claim 60, wherein the antibody molecule is rituximab. 62. The method of claim 59, wherein the antibody molecule is an anti-CD38 antibody molecule. 63. The method of claim 62, wherein the anti-CD38 antibody molecule is daratumumab. 64. The method of claim 59, wherein the antibody molecule is an anti-CD19 antibody molecule. 65. The method of claim 59, wherein the antibody molecule is an anti-Her2/neu antibody molecule. 66. The method of claim 59, wherein the antibody molecule is an anti-EGFR antibody molecule. 67. The method of claim 59, wherein the antibody molecule is an anti-CD30 antibody molecule. 68. The method of claim 59, wherein the antibody molecule is an anti-CD33 antibody molecule. 69. The method of claim 53, wherein the cancer is a hematological cancer. 70. The method of claim 69, wherein the hematological cancer is selected from the group consisting of: acute lymphoblastic leukemia (ALL), T-ALL, B-ALL, acute myelogenous leukemia (AML), Non-Hodgkin lymphoma, B-lymphoblastic leukemia/lymphoma; diffuse large B cell lymphoma (DLBCL); B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic lymphocytic leukemia (CLL), chronic myelocytic leukemia (CML), Burkitt's lymphoma, follicular lymphoma, SLL, marginal zone lymphoma, CNS lymphoma, Richter's Syndrome, multiple myeloma, myelofibrosis, polycythemia vera, cutaneous T-cell lymphoma, MGUS, myelodysplastic syndrome (MDS), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma and anaplastic large cell lymphoma. 71. The method of claim 70, wherein the hematological cancer is acute myelogenous leukemia (AML), diffuse large B cell lymphoma (DLBCL) or Burkitt's lymphoma. 72. The method of claim 53, wherein the cancer is a solid tumor. 73. The method of claim 72, wherein the cancer is a cancer of a tissue selected from the group consisting of: lung, pancreas, breast, liver, ovary, testicle, kidney, bladder, spine, brain, cervix, endometrium, colon/rectum, anus, esophagus, gallbladder, gastrointestinal tract, skin, prostate, pituitary, stomach, uterus, vagina, and thyroid. 74. The method of claim 53, wherein the cancer is selected from the group consisting of: pancreatic cancer, ovarian cancer, breast cancer, stomach cancer, colon cancer, prostate cancer, and uterine cancer. 75. The method of claim 53, wherein the pharmaceutical composition is administered subcutaneously. 76. The method of claim 53, wherein the pharmaceutical composition is administered intravenously.

Details for Patent 10,442,858

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2035-09-21
Janssen Biotech, Inc.	DARZALEX	daratumumab	Injection	761036	11/16/2015		2035-09-21
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2035-09-21